Landos Biopharma Inc (LABP)
22.93
+0.13
(+0.58%)
USD |
NASDAQ |
May 23, 16:00
Landos Biopharma Research and Development Expense (TTM): 11.82M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 11.82M |
| December 31, 2023 | 12.00M |
| September 30, 2023 | 12.27M |
| June 30, 2023 | 14.06M |
| March 31, 2023 | 18.21M |
| December 31, 2022 | 25.68M |
| September 30, 2022 | 35.71M |
| June 30, 2022 | 40.19M |
| Date | Value |
|---|---|
| March 31, 2022 | 45.11M |
| December 31, 2021 | 41.56M |
| September 30, 2021 | 38.08M |
| June 30, 2021 | 35.70M |
| March 31, 2021 | 27.90M |
| December 31, 2020 | 25.34M |
| September 30, 2020 | 18.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
11.82M
Minimum
Mar 2024
45.11M
Maximum
Mar 2022
26.82M
Average
25.68M
Median
Dec 2022
Research and Development Expense (TTM) Benchmarks
| AbbVie Inc | 7.322B |
| Fusion Pharmaceuticals Inc | 75.54M |
| Masimo Corp | 172.50M |
| Kinnate Biopharma Inc (DELISTED) | 90.77M |
| Invivyd Inc | 162.62M |